Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

161. Review: second-generation antipsychotics improve response in paediatric bipolar disorder, but are associated with adverse events

Review: second-generation antipsychotics improve response in paediatric bipolar disorder, but are associated with adverse events Review: second-generation antipsychotics improve response in paediatric bipolar disorder, but are associated with adverse events | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: second-generation antipsychotics improve response in paediatric bipolar disorder, but are associated with adverse events

2012 Evidence-Based Mental Health

162. Systematic review and meta-analysis: High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events

Systematic review and meta-analysis: High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via (...) intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events Article Text Therapeutics Systematic review and meta-analysis High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events Anthony A Bavry Statistics from Altmetric.com Commentary on: Patti G , Cannon CP , Murphy SA , et al . Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary

2012 Evidence-Based Medicine

163. Adverse events over two years after retropubic or transobturator midurethral sling surgery: findings from the Trial of Midurethral Slings (TOMUS) study Full Text available with Trip Pro

Adverse events over two years after retropubic or transobturator midurethral sling surgery: findings from the Trial of Midurethral Slings (TOMUS) study To describe surgical complications in 597 women over a 24-month period after randomization to retropubic or transobturator midurethral slings.During the Trial of Midurethral Slings study, the Data Safety Monitoring Board regularly reviewed summary reports of all adverse events using the Dindo Surgical Complication Scale. Logistic regression (...) models were created to explore associations between clinicodemographic factors and surgical complications.A total of 383 adverse events were observed among 253 of the 597 women (42%). Seventy-five adverse events (20%) were classified as serious (serious adverse events); occurring in 70 women. Intraoperative bladder perforation (15 events) occurred exclusively in the retropubic group. Neurologic adverse events were more common in the transobturator group than in retropubic (32 events vs 20 events

2012 EvidenceUpdates Controlled trial quality: uncertain

164. Evaluating preventable adverse safety events after elective lower extremity procedures Full Text available with Trip Pro

Evaluating preventable adverse safety events after elective lower extremity procedures Improving patient safety has become a national priority. Patient safety indicators (PSIs) are validated tools to identify potentially preventable adverse events. No studies currently exist for evaluating lower extremity (LE) vascular procedures and the occurrence of PSIs.The Nationwide Inpatient Sample (2003-2007) was queried for elective LE angioplasty (endo) and bypass (open). PSIs appropriate to surgery (...) to have lower mortality rates overall, but were found to have a greater number of safety events occur primarily due to bleeding complications in women and the elderly. PSIs were associated with advanced age, black race, and comorbidities. Adverse events added significant cost, occurred more frequently in teaching and large hospitals, and future organizational analysis may improve safety and reduce cost.Copyright © 2011 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

2011 EvidenceUpdates

165. Emergency hospitalizations for adverse drug events in older americans. Full Text available with Trip Pro

Emergency hospitalizations for adverse drug events in older americans. Adverse drug events are important preventable causes of hospitalization in older adults. However, nationally representative data on adverse drug events that result in hospitalization in this population have been limited.We used adverse-event data from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project (2007 through 2009) to estimate the frequency and rates (...) of hospitalization after emergency department visits for adverse drug events in older adults and to assess the contribution of specific medications, including those identified as high-risk or potentially inappropriate by national quality measures.On the basis of 5077 cases identified in our sample, there were an estimated 99,628 emergency hospitalizations (95% confidence interval [CI], 55,531 to 143,724) for adverse drug events in U.S. adults 65 years of age or older each year from 2007 through 2009. Nearly half

2011 NEJM

166. One-year prognosis after syncope and the failure of the ROSE decision instrument to predict one-year adverse events (Abstract)

One-year prognosis after syncope and the failure of the ROSE decision instrument to predict one-year adverse events We investigate the incidence of adverse events at 1 year in the cohort of emergency department (ED) syncope patients enrolled in the original Risk Stratification of Syncope in the Emergency Department (ROSE) study, the time to adverse event, and the test performance of the ROSE decision instrument to detect events at 1 year.This report details the 1-year follow-up of adult syncope (...) international syncope studies. We have defined the proportion of patients with cardiovascular serious outcome at 1 year and have shown that most events occurred in the first month, with decreased frequency of events observed after that time especially marked for cardiovascular serious outcome. More than 50% of the outcomes observed, however, occurred after the first month. The ROSE decision instrument does not perform well at predicting 1-year outcome of ED syncope patients.Copyright © 2011 American College

2011 EvidenceUpdates

167. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. Full Text available with Trip Pro

High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. To examine the prevalence and patterns of high risk prescribing, defined as potentially inappropriate prescribing of drugs to primary care patients particularly vulnerable to adverse drug events.Cross sectional population database analysis.General practices in Scotland.315 Scottish general practices with 1.76 million registered (...) patients, 139 404 (7.9%) of whom were defined as particularly vulnerable to adverse drug events because of age, comorbidity, or co-prescription.How reliably each of 15 indicators-four each for non-steroidal anti-inflammatory drugs, co-prescription with warfarin, and prescribing in heart failure, two for dose instructions for methotrexate, and one for antipsychotic prescribing in dementia-and a composite of all 15 could distinguish practices in terms of their rates of high risk prescribing

2011 BMJ

168. Paid malpractice claims for adverse events in inpatient and outpatient settings. Full Text available with Trip Pro

Paid malpractice claims for adverse events in inpatient and outpatient settings. An analysis of paid malpractice claims may provide insight into the prevalence and seriousness of adverse medical events in the outpatient setting.To report and compare the number, magnitude, and type of paid malpractice claims for events in inpatient and outpatient settings.Retrospective analysis of malpractice claims paid on behalf of physicians in outpatient and inpatient settings using data from the National (...) Practitioner Data Bank from 2005 through 2009. We evaluated trends in claims paid by setting, characteristics of paid claims, and factors associated with payment amount.Number of paid claims, mean and median payment amounts, types of errors, and outcomes of errors.In 2009, there were 10,739 malpractice claims paid on behalf of physicians. Of these paid claims, 4910 (47.6%; 95% confidence interval [CI], 46.6%-48.5%) were for events in the inpatient setting, 4448 (43.1%; 95% CI, 42.1%-44.0%) were for events

2011 JAMA

169. Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years Full Text available with Trip Pro

Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years (...) or with inactivated influenza vaccine, for children younger than five years, considering the impact of adverse events. The authors concluded that the live attenuated vaccine was similar in cost-effectiveness to the inactivated vaccine, under a wide range of assumptions on the incidence of adverse events. The methods were valid and should ensure that the authors’ conclusions are robust. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study objective This study assessed the cost

2011 NHS Economic Evaluation Database.

170. Comparison of rates of adverse events in adolescent and adult women undergoing medical abortion: population register based study. Full Text available with Trip Pro

Comparison of rates of adverse events in adolescent and adult women undergoing medical abortion: population register based study. To determine the risks of short term adverse events in adolescent and older women undergoing medical abortion.Population based retrospective cohort study.Finnish abortion register 2000-6.All women (n = 27,030) undergoing medical abortion during 2000-6, with only the first induced abortion analysed for each woman.Incidence of adverse events (haemorrhage, infection (...) cohort (5.7% v 3.7%, P < 0.001). The incidence of adverse events among adolescents was similar or lower than that among the adults. The risks of haemorrhage (adjusted odds ratio 0.87, 95% confidence interval 0.77 to 0.99), incomplete abortion (0.69, 0.59 to 0.82), and surgical evacuation (0.78, 0.67 to 0.90) were lower in the adolescent cohort. In subgroup analysis of primigravid women, the risks of incomplete abortion (0.68, 0.56 to 0.81) and surgical evacuation (0.75, 0.64 to 0.88) were lower

2011 BMJ

171. Literature review: do rapid response systems reduce the incidence of major adverse events in the deteriorating ward patient? Full Text available with Trip Pro

Literature review: do rapid response systems reduce the incidence of major adverse events in the deteriorating ward patient? To conduct a literature review that explores the impact of rapid response systems on reducing major adverse events experienced by deteriorating ward patients.Patients located on hospitals wards are frequently older, have multiple co-morbidities and are often at risk of life-threatening clinical deterioration. Rapid response systems have been developed and implemented (...) effectiveness of rapid response systems in reducing major adverse events in deteriorating ward patients remains inconclusive. Six studies demonstrated that the introduction of a rapid response systems positively impacted on patient outcomes, but three studies demonstrated no positive impact on patient outcomes. Nursing staff appear reluctant to use rapid response systems; the rationale for this is unclear. However, the continued underuse and inactivation may be one reason why research findings evaluating

2011 EvidenceUpdates

172. Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study) (Abstract)

Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study) In large clinical trials enrolling patients with acute coronary syndromes, a high loading dose of clopidogrel (600 mg) has been found to be more effective compared to a low loading dose (300 mg). However, the applicability of these data to stable patients who undergo elective (...) percutaneous coronary intervention is still unclear. A total of 400 patients who underwent elective PCI were prospectively randomized to receive either 600 mg (n = 200) or 300 mg (n = 200) of clopidogrel, followed by a daily maintenance dose of 75 mg. The primary end point was the presence of major adverse cardiovascular events (combined death, myocardial infarction, acute neurologic event, stent thrombosis, and need for percutaneous or surgical revascularization of the target vessel) during

2011 EvidenceUpdates Controlled trial quality: uncertain

173. Risk of Serious Adverse Cardiovascular (CV) Events with Varenicline (Champix) Comment on Systematic Review and Meta?analysis

Risk of Serious Adverse Cardiovascular (CV) Events with Varenicline (Champix) Comment on Systematic Review and Meta?analysis RxFiles Trial Summary Q&A www.RxFiles.ca - July 2011 Could the NNH really be 28? Risk of Serious Adverse Cardiovascular (CV) Events with Varenicline (Champix) Comment on Systematic Review and Meta-analysis 1 Findings at a glance In 14 randomized placebo controlled trials with 8216 participants, varenicline was associated with an increase in serious adverse CV events. o (...) . ? In 14 trials that analysed 8216 patients on varenicline vs placebo, the NNH was 417. In 0 trials analysing 0 patients, but all of whom were at much higher risk, this extrapolated NNH would be 28, assuming that the proposed odds ratio holds true. Note that the absolute risk of continuing smoking would also be a major factor to consider in weighing the risk/benefit of therapy. Extras: RxFiles Meta Q&A – July 2011: Risk of Serious Adverse Cardiovascular (CV) Events with Varenicline (Champix, Chantix

2011 RxFiles

174. Dronedarone (Multaq?): cardiovascular, hepatic and pulmonary adverse events

Dronedarone (Multaq?): cardiovascular, hepatic and pulmonary adverse events Enzira/CSL Biotherapies and Viroflu/Inflexal V influenza vaccines and risk of febrile reactions in children under 5 years - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Enzira/CSL Biotherapies and Viroflu/Inflexal V influenza vaccines and risk of febrile reactions in children under 5 years Use alternative vaccines in under 5s and report suspected adverse reactions Published 11 December 2014 From (...) , are reported to us. If you do not have this information at hand, please still report to us and we will follow-up with you for further information. Reports of febrile convulsions or any suspected adverse reaction can be sent online to Further information BNF section 14.4 Article citation: Drug Safety Update Oct 2011, vol 5 issue 3: S1. Published 11 December 2014 Explore the topic Is this page useful? Thank you for your feedback Help us improve GOV.UK Don’t include personal or financial information like your

2011 MHRA Drug Safety Update

175. Dronedarone (Multaq?): cardiovascular, hepatic and pulmonary adverse events ? new restrictions and monitoring requirements

Dronedarone (Multaq?): cardiovascular, hepatic and pulmonary adverse events ? new restrictions and monitoring requirements Dronedarone (Multaq▼): cardiovascular, hepatic and pulmonary adverse events – new restrictions and monitoring requirements - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Dronedarone (Multaq▼): cardiovascular, hepatic and pulmonary adverse events – new restrictions and monitoring requirements Following new evidence of cardiovascular, hepatic and pulmonary (...) Atrial fibriLLAtion outcome Study using dronedarone on top of standard therapy) had been investigating the potential clinical benefit of dronedarone (added to standard therapy) in patients older than 65 years with permanent atrial fibrillation in the reduction of: major cardiovascular (CV) events (ie, stroke, systemic arterial embolism, myocardial infarction, or cardiovascular death) unplanned cardiovascular hospitalisation or death from any cause The study was prematurely terminated in July 2011

2011 MHRA Drug Safety Update

176. Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis

Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis Smits NA, Duru N, Bijlsma JW, Jacobs JW CRD summary The review concluded that intravenous glucocorticoid pulse therapy resulted in a high adverse event rate; cardiovascular adverse events were (...) the most commonly reported. The review had methodological and data limitations that limit the reliability of the authors’ conclusions. Authors' objectives To determine the adverse events associated with intravenous pulse glucocorticoids for inflammatory diseases. Searching PubMed, EMBASE and The Cochrane Library were searched to October 2009 for articles published in English. Full search strategies were reported. Reference lists of retrieved studies were searched. Study selection Full text randomised

2011 DARE.

177. Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials

Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

178. Systematic review: Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel

Systematic review: Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel | BMJ Evidence-Based Medicine We use cookies (...) Username * Password * your user name or password? You are here Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel Article Text Prognosis Systematic review Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention

2011 Evidence-Based Medicine

179. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis

Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

180. Association between recent stressful life events and prevalence of depression, anxiety and PTSD differs according to exposure to childhood adversity

Association between recent stressful life events and prevalence of depression, anxiety and PTSD differs according to exposure to childhood adversity Association between recent stressful life events and prevalence of depression, anxiety and PTSD differs according to exposure to childhood adversity | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) and PTSD differs according to exposure to childhood adversity Article Text Prevalence Association between recent stressful life events and prevalence of depression, anxiety and PTSD differs according to exposure to childhood adversity Statistics from Altmetric.com Question Question Does the relationship between recent past-year stressful life events and prevalence of psychiatric disorder vary according to exposure to childhood adversity (CA)? Population 34 653 civilian, non-institutionalised adults

2011 Evidence-Based Mental Health